A comprehensive comparison of these growth hormone-related research peptides, examining their distinct receptor pathways, signaling mechanisms, and applications in preclinical GH axis research.
Part of the PeptidesATX Research Hub
The growth hormone (GH) axis is regulated by multiple signaling systems that converge on pituitary somatotroph cells. CJC (No Dac) and Ipamorlin represent two fundamentally different approaches to studying GH regulation—one mimicking hypothalamic GHRH signaling, the other mimicking peripheral ghrelin signaling.
Understanding the mechanistic differences between these compounds is essential for researchers designing studies in neuroendocrine regulation, GH/IGF-1 axis function, and related metabolic pathways. This comparison examines their receptor targets, signaling cascades, and appropriate research applications.
CJC (No Dac) is a GHRH analog that activates GHRH receptors (GHRH-R), while Ipamorlin is a growth hormone secretagogue that activates ghrelin receptors (GHS-R1a). These distinct receptor systems provide complementary tools for investigating different aspects of GH axis regulation.
Before examining specific mechanisms, it's important to understand how these compounds are classified within the broader landscape of GH-related research peptides.
| Property | CJC (No Dac) | Ipamorlin |
|---|---|---|
| Classification | GHRH analog | Growth hormone secretagogue (GHS) |
| Primary Receptor | GHRH-R | GHS-R1a (ghrelin receptor) |
| Receptor Location | Pituitary somatotrophs | Pituitary, hypothalamus |
| Signaling Pathway | Gs-cAMP-PKA | Gq-PLC-IP3/DAG |
| Endogenous Analog | Hypothalamic GHRH | Stomach-derived ghrelin |
| Structural Basis | Modified GHRH (1-29) | Pentapeptide ghrelin mimetic |
CJC (No Dac) is a synthetic analog of growth hormone-releasing hormone, modified to resist enzymatic degradation while maintaining receptor binding activity. Two variants exist: CJC (No Dac) with DAC (Drug Affinity Complex) and CJC (No Dac) without DAC (also called Modified GRF 1-29).
CJC (No Dac) binds to the GHRH receptor, a class B G protein-coupled receptor (GPCR) expressed primarily on anterior pituitary somatotroph cells. Key aspects of this signaling pathway include:
CJC (No Dac) is valuable for studying:
Researchers should note the distinction between CJC (No Dac) variants:
Ipamorlin is a synthetic pentapeptide that acts as a selective growth hormone secretagogue. Unlike natural ghrelin, Ipamorlin demonstrates high selectivity for GH release with minimal effects on other pituitary hormones.
Ipamorlin binds to the growth hormone secretagogue receptor type 1a (GHS-R1a), triggering a distinct signaling cascade:
Research indicates Ipamorlin has a notably selective profile compared to other GH secretagogues:
Ipamorlin is valuable for studying:
The fundamental difference between CJC (No Dac) and Ipamorlin lies in their downstream signaling cascades, despite both ultimately promoting GH release.
| Signaling Component | CJC (No Dac) (GHRH-R) | Ipamorlin (GHS-R1a) |
|---|---|---|
| G Protein | Gs (stimulatory) | Gq (phospholipase-activating) |
| Primary Effector | Adenylyl cyclase | Phospholipase C |
| Second Messenger | cAMP | IP3 + DAG |
| Kinase Activated | PKA | PKC |
| Calcium Source | Extracellular influx | ER stores + extracellular |
| Transcription Factor | CREB phosphorylation | Multiple pathways |
The distinct signaling pathways mean CJC (No Dac) and Ipamorlin can be used to study different aspects of somatotroph function. CJC (No Dac) is ideal for cAMP/PKA pathway studies, while Ipamorlin is suited for investigating PLC/PKC-mediated GH release mechanisms.
Both compounds influence the broader GH/IGF-1 axis, but through different entry points in the regulatory cascade.
The GH axis involves complex feedback loops:
GH released through either pathway acts on:
Choosing between CJC (No Dac) and Ipamorlin depends on the specific research questions being addressed.
Both peptides require appropriate handling for research applications.
Researchers studying GH axis regulation may also consider:
The decision between CJC (No Dac) and Ipamorlin depends on the specific aspects of GH axis regulation being investigated:
Both compounds represent valuable tools for GH axis research, and their appropriate application depends on aligning compound mechanisms with specific research objectives.
CJC (No Dac) is a GHRH (growth hormone-releasing hormone) analog that acts on GHRH receptors in the pituitary, while Ipamorlin is a growth hormone secretagogue that acts on ghrelin receptors (GHS-R). They stimulate GH release through distinct receptor pathways, making them valuable for studying different aspects of GH axis regulation.
Researchers study these compounds together because they act on different receptor systems that converge on GH release. CJC (No Dac) mimics hypothalamic GHRH signaling while Ipamorlin mimics ghrelin signaling. Studying both allows investigation of how these pathways interact. The reference finding that they reinforce each other comes from healthy men (a GHRH plus GHRP combination released more GH than either alone; Bowers et al., J Clin Endocrinol Metab 1990); in laboratory models the interaction is species-dependent — more than additive in rat pituitary cells, only additive in bovine cells (Rico et al., J Physiol Biochem 1999).
CJC (No Dac) targets the GHRH receptor (GHRH-R), a G protein-coupled receptor expressed on pituitary somatotroph cells. Activation of this receptor stimulates cAMP production and subsequent GH synthesis and release.
Ipamorlin targets the growth hormone secretagogue receptor (GHS-R1a), also known as the ghrelin receptor. This receptor is expressed in the pituitary and hypothalamus, and its activation promotes GH release through mechanisms distinct from GHRH signaling.
Research indicates Ipamorlin is highly selective for GH release with minimal effects on cortisol, prolactin, or ACTH. CJC (No Dac), as a GHRH analog, primarily affects the GH/IGF-1 axis. This selectivity profile makes each compound useful for studying specific aspects of neuroendocrine regulation without confounding effects from other hormone changes.
Access research-grade peptides and quality documentation for your laboratory investigations.
CJC (No Dac)/Ipamorlin Blend Tesamorelin (GHRH Analog) Certificates of AnalysisDisclaimer: These compounds are intended for laboratory research use only. They are not approved for human or veterinary use. All research must be conducted in accordance with applicable institutional and regulatory guidelines.